Bender Robert & Associates Sells 1,061 Shares of Illumina, Inc. (NASDAQ:ILMN)

Bender Robert & Associates reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 46,164 shares of the life sciences company’s stock after selling 1,061 shares during the quarter. Illumina comprises 1.6% of Bender Robert & Associates’ holdings, making the stock its 19th biggest position. Bender Robert & Associates’ holdings in Illumina were worth $6,428,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Brown Brothers Harriman & Co. raised its stake in shares of Illumina by 460.9% during the first quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock worth $45,000 after buying an additional 106 shares during the last quarter. State of Wyoming acquired a new stake in shares of Illumina in the 2nd quarter valued at approximately $32,000. Penserra Capital Management LLC bought a new position in shares of Illumina during the first quarter worth $64,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Illumina in the 3rd quarter valued at $30,000. Finally, VisionPoint Advisory Group LLC increased its position in shares of Illumina by 344.6% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after buying an additional 193 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ILMN shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $253.00 price target on shares of Illumina in a research note on Tuesday, April 9th. TD Cowen downgraded shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price objective for the company. in a research note on Thursday, January 4th. Barclays lifted their target price on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. StockNews.com raised Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Finally, Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Wednesday, April 10th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $167.70.

Insiders Place Their Bets

In other Illumina news, CEO Jacob Thaysen bought 7,330 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were purchased at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the transaction, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.17% of the company’s stock.

Illumina Stock Performance

NASDAQ:ILMN traded down $1.60 during mid-day trading on Thursday, hitting $116.69. 1,810,233 shares of the stock were exchanged, compared to its average volume of 1,763,704. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The firm’s 50-day simple moving average is $134.31 and its 200 day simple moving average is $128.15. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $232.23. The stock has a market capitalization of $18.58 billion, a price-to-earnings ratio of -16.12 and a beta of 1.19.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter last year, the firm earned $0.14 earnings per share. The company’s revenue was up 3.6% on a year-over-year basis. As a group, equities analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.